文献速递泌尿生殖腹部技术与安全CT

静脉注射碘克沙醇是否与急性肾损伤、透析或死亡风险增加相关?一项倾向性评分校正研究

Is Intravenous Administration of Iodixanol Associated with Increased Risk of Acute Kidney Injury, Dialysis, or Mortality? A Propensity Score-adjusted Study.
PubMed 文献 · Radiology · 2017-07-13

本研究比较了静脉注射等渗对比剂碘克沙醇320后行增强CT与行平扫CT患者急性肾损伤、急诊透析及短期死亡率。倾向性评分校正后,各CKD亚组中碘克沙醇组急性肾损伤、透析及死亡率均未显著高于平扫组,敏感性分析结果相似。作者结论认为静脉注射碘克沙醇并非急性肾损伤、透析或死亡的独立危险因素。

要点

  • 各CKD亚组中碘克沙醇组与平扫组急性肾损伤、透析及死亡率均无显著差异。
  • 急性肾损伤OR为0.74-0.91,透析OR为0.74-2.00,死亡率OR为0.98-1.24。
  • 在感知对比剂肾损伤风险最高的患者中,静脉碘克沙醇非独立危险因素。

核心结论

  • 在感知对比剂后急性肾损伤风险最高的患者中,静脉注射碘克沙醇行增强CT并非急性肾损伤、透析或死亡的独立危险因素。

研究设计与样本

  • 倾向性评分校正研究,纳入2003年1月至2014年12月期间行碘克沙醇增强CT或平扫CT的患者共5758例,其中1-2期CKD 1538例、3期CKD 2899例、4-5期CKD 1321例,按CKD分期分层后进行倾向性评分分层与匹配。

诊断标准与关键数值

  • CKD分期标准:1-2期eGFR≥60 mL/min/1.73 m²,3期eGFR 30-59 mL/min/1.73 m²,4-5期eGFR<30 mL/min/1.73 m²。
  • 倾向性评分校正后,碘克沙醇组 vs 平扫组急性肾损伤OR为0.74-0.91(P=.16-.69),透析OR为0.74-2.00(P=.42-.76),死亡率OR为0.98-1.24(P=.39-.88)。
  • 所有CKD亚组中,碘克沙醇组急性肾损伤、透析及死亡率均未显著高于平扫组。

临床应用与阅片要点

  • 报告增强CT时可参考:静脉注射碘克沙醇后急性肾损伤、透析及死亡风险与平扫CT相比无显著差异。
  • 对CKD患者行碘克沙醇增强CT时,上述倾向性评分校正结果可供临床沟通参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To compare the rates of acute kidney injury (AKI), emergent dialysis, and short-term mortality between patients who underwent intravenous administration of the iso-osmolar contrast material (IOCM) iodixanol 320 and patients who underwent a noncontrast computed tomography (CT) examination. Materials and Methods Study design and implementation were overseen by an institutional review board and conformed to HIPAA guidelines on patient data integrity. All patients who underwent an iodixanol-enhanced (IOCM group) or a noncontrast (noncontrast group) CT examination from January 2003 to December 2014 were identified. Patients were subdivided into subgroups of those with stage 1-2 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR], ≥ 60 mL/min/1.73 m2), those with stage 3 CKD (eGFR, 30-59 mL/min/1.73 m2), and those with stage 4-5 CKD (eGFR < 30 mL/min/1.73 m2) and separately underwent propensity score stratification and matching. Rates of AKI, emergent dialysis, and mortality were compared between IOCM and noncontrast groups. Additional analyses incorporating intravenous fluid administration, including additional CT studies at other sites within a single institution, and a paired analysis of patients who underwent both IOCM and noncontrast CT studies during the study time frame, were also performed. Results A total of 5758 patients (1538 with stage 1-2 CKD, 2899 with stage 3 CKD, and 1321 with stage 4-5 CKD) were included in the study. After propensity score adjustment, rates of AKI, dialysis, and mortality were not significantly higher in the IOCM group compared with the noncontrast group for all CKD subgroups (AKI odds ratios [ORs], 0.74-0.91, P = .16-0.69; dialysis ORs, 0.74-2.00, P = .42-.76; mortality ORs, 0.98-1.24, P = .39-.88). Sensitivity analyses yielded similar results. Conclusion Among patients at the highest perceived risk of postcontrast AKI, intravenous administration of iodixanol for contrast material enhanced CT was not an independent risk factor for AKI, dialysis, or mortality. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. McDonald JS, McDonald RJ, Williamson EE, et al. Is Intravenous Administration of Iodixanol Associated with Increased Risk of Acute Kidney Injury, Dialysis, or Mortality? A Propensity Score-adjusted Study. Radiology. 2017. PMID: 28708022. doi:10.1148/radiol.2017161573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。